Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Bariatric Surgery

Serum asprosin levels and bariatric surgery outcomes in obese adults



Asprosin is a novel fasting-induced glucogenic and orexigenic protein hormone. The clinical function of asprosin in obesity is currently unknown. This study investigated the association between asprosin abundance and the outcome of bariatric surgery.


Patients with body mass index more than 35 kg/m2 were recruited for the Obesity and Clock for Elegant Aging Registry in 2011—2016. Body weight changes, blood sugar, and asprosin were assessed in 117 patients receiving bariatric surgery and 57 non-obese subjects as normal control. Primary outcomes of excess weight loss percentage at 6 months after bariatric surgery were determined at follow-up.


Asprosin levels were significantly higher in obese patients than in non-obese subjects (2360 ± 5094 vs. 307 ± 832 ng/ml, p < 0.0001). Multivariate analyses showed a significant association of asprosin abundance with excess body weight loss percentage at 6 months after surgery (p < 0.0001). After adjusted for age, sex, smoking, HbA1c, cholesterol, and triglyceride, serum asprosin level was the only independent predictor of 6 months excess weight loss percentage after bariatric surgery. Asprosin levels decreased significantly 6 months after bariatric surgery (162.2 ± 169.1 ng/ml). Furthermore, there was no association between asprosin and serum glucose levels in our study.


This study provides novel evidence that higher asprosin concentrations before bariatric surgery were associated with the weight reduction magnitude at 6 months after surgery. Further studies are warranted to investigate whether asprosin has direct functions to modulate body weight regulation in humans after bariatric surgery.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4


  1. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27.

    Article  Google Scholar 

  2. Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med. 1998;105:145–50.

    Article  CAS  Google Scholar 

  3. Sharma AM. Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord. 2002;26(Suppl 4):S5–7.

    Article  CAS  Google Scholar 

  4. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T. et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2016;40:1310–9.

    Article  CAS  Google Scholar 

  5. Wang C-Y, Kim H-H, Hiroi Y, Sawada N, Salomone S, Benjamin LE, et al. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal. 2009;2:ra11.

    Article  Google Scholar 

  6. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–81.

    Article  Google Scholar 

  7. Kang JG, Park C-Y. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012;36:13–25.

    Article  Google Scholar 

  8. Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf. 2012;11:459–71.

    Article  CAS  Google Scholar 

  9. Crujeiras AB, Gomez-Arbelaez D, Zulet MA, Carreira MC, Sajoux I, de Luis D. et al. Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress?. Int J Obes. 2017;41:1570–8.

    Article  CAS  Google Scholar 

  10. Buchwald H. Impact of bariatric surgery on life expectancy in severely obese patients with diabetes. Ann Surg. 2017;266:e57.

    Article  Google Scholar 

  11. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65.

    Article  Google Scholar 

  12. Wolfe BL, Terry ML. Expectations and outcomes with gastric bypass surgery. Obes Surg. 2006;16:1622–9.

    Article  Google Scholar 

  13. Kim Y, Crookes PF. Complications of bariatric surgery, essentials and controversies in bariatric surgery, Huang CK, IntechOpen. 2014; 81–82.

  14. Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157:1279–91.

    Article  CAS  Google Scholar 

  15. Gavrieli A, Panagiotou G, Mantzoros CS. Leptin administration in physiological or pharmacological doses does not alter circulating irisin levels in humans. Int J Obes. 2016;40:1461–3.

    Article  CAS  Google Scholar 

  16. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165:566–79.

    Article  CAS  Google Scholar 

  17. Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23:1444–53.

    Article  CAS  Google Scholar 

  18. Greenhill C. Liver: asprosin—new hormone involved in hepatic glucose release. Nat Rev Endocrinol. 2016;12:312.

    Article  CAS  Google Scholar 

  19. Acara AC, Bolatkale M, Kızıloğlu İ, İbişoğlu E, Can Ç. A novel biochemical marker for predicting the severity of acute coronary syndrome with unstable angina pectoris: Asprosin. Am J Emerg Med. 2017.

    Article  Google Scholar 

  20. Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2017.

    Article  CAS  Google Scholar 

  21. Isaacs M, Brzozowska M, Xu A, Greenfield J, Center J. Effects of bariatric surgery on adipokine profile over 12 months in humans. Obes Res Clin Pract. 2014;8:50.

    Article  Google Scholar 

  22. Ionut V, Burch M, Youdim A, Bergman RN. Gastrointestinal hormones and bariatric surgery‐induced weight loss. Obesity. 2013.

  23. Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2012;9:590–8.

    Article  Google Scholar 

  24. Wang C-Y, Liao JK. A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol. 2012;821:421–33.

    Article  CAS  Google Scholar 

  25. Kotnik P, Knapič E, Kokošar J, Kovač J, Jerala R, Battelino T, et al. Identification of novel alleles associated with insulin resistance in childhood obesity using pooled-DNA genome wide association study approach. Int J Obes. 2017.

    Article  CAS  Google Scholar 

  26. Jedrychowski MP, Wrann CD, Paulo JA, Gerber KK, Szpyt J, Robinson MM, et al. Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab. 2015;22:734–40.

    Article  CAS  Google Scholar 

  27. Wang C-Y. Circadian rhythm, exercise, and heart. Acta Cardiol Sin. 2017;33:539–41.

    PubMed  PubMed Central  Google Scholar 

  28. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010;330:1349–54.

    Article  CAS  Google Scholar 

Download references


We thank Mei-Hsiu Lin, Hui-Ting Su, Chi-Wen Cheng, and Tsu-Hui Yeh for technical assistance. C-YW received support from the National Health Research Institute (NHRI-EX106-10617SI), National Science Council (105-2628-B-182-009-MY4), and Chang Gung Memorial Hospital (CMRPG3H0131, CMRPG3H0271, and CMRPG3H0841). M-SW received support from Chang Gung Memorial Hospital (CMRPG3E1852-3 and CMRPG3E1892-3). T-SY received support from Chang Gung Memorial Hospital (CMRPG3C311 and CORPG3C0111-2). We thank the members of the OCEAN (Obesity and Clock for Elegant AgiNg) registry.

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Chao-Yung Wang or Ta-Sen Yeh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, CY., Lin, TA., Liu, KH. et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes 43, 1019–1025 (2019).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links